Trial Profile
A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 03 Jul 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 03 Jul 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 25 May 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.